Rubraca

Overview

rucaparib

PARP inhibitor

• CYP1A2 inhibitor, moderate
• CYP2C9 inhibitor, weak
• CYP2C19 inhibitor, weak
• CYP3A4 inhibitor, weak
• BCRP inhibitor
• P-gp inhibitor, weak
• myelosuppressive oncologic agent
• photosensitivity
• prolongs QT interval (known)

Contraindicated

• cisapride
Rubraca (rucaparib)

+

cisapride

1 interaction

Contraindicated

rucaparib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• colchicine
Rubraca (rucaparib)

+

colchicine

2 interactions

Contraindicated

rucaparib + colchicine

CV RISK REDUCTION: monitor CBC; consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or monitor CBC; consider decr. colchicine dose during and x14 days after rucaparib use: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• dronedarone
Rubraca (rucaparib)

+

dronedarone

3 interactions

Contraindicated

rucaparib + dronedarone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eliglustat
Rubraca (rucaparib)

+

eliglustat

1 interaction

Contraindicated

rucaparib + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• fezolinetant
Rubraca (rucaparib)

+

fezolinetant

1 interaction

Contraindicated

rucaparib + fezolinetant

contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metab. inhibited)

• levoketoconazole
Rubraca (rucaparib)

+

levoketoconazole

2 interactions

Contraindicated

rucaparib + levoketoconazole

contraindicated: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• pimozide
Rubraca (rucaparib)

+

pimozide

1 interaction

Contraindicated

rucaparib + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

Avoid/Use Alternative

• adagrasib
Rubraca (rucaparib)

+

adagrasib

2 interactions

Avoid/Use Alternative

rucaparib + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alosetron
Rubraca (rucaparib)

+

alosetron

2 interactions

Avoid/Use Alternative

rucaparib + alosetron

use alternative: combo may incr. alosetron levels, risk of adverse effects (hepatic metab. inhibited)

• alpelisib
Rubraca (rucaparib)

+

alpelisib

2 interactions

Avoid/Use Alternative

rucaparib + alpelisib

use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

• aminolevulinic acid topical
Rubraca (rucaparib)

+

aminolevulinic acid topical

3 interactions

Avoid/Use Alternative

rucaparib + aminolevulinic acid topical

avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)

• amiodarone
Rubraca (rucaparib)

+

amiodarone

1 interaction

Avoid/Use Alternative

rucaparib + amiodarone

use alternative or monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• anagrelide
Rubraca (rucaparib)

+

anagrelide

1 interaction

Avoid/Use Alternative

rucaparib + anagrelide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Rubraca (rucaparib)

+

apalutamide

1 interaction

Avoid/Use Alternative

rucaparib + apalutamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Rubraca (rucaparib)

+

apomorphine

3 interactions

Avoid/Use Alternative

rucaparib + apomorphine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arsenic trioxide
Rubraca (rucaparib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

rucaparib + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Rubraca (rucaparib)

+

artemether/ lumefantrine

2 interactions

Avoid/Use Alternative

rucaparib + artemether/ lumefantrine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Rubraca (rucaparib)

+

asenapine

2 interactions

Avoid/Use Alternative

rucaparib + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Rubraca (rucaparib)

+

bedaquiline

2 interactions

Avoid/Use Alternative

rucaparib + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bendamustine
Rubraca (rucaparib)

+

bendamustine

1 interaction

Avoid/Use Alternative

rucaparib + bendamustine

consider alternatives: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• bosentan
Rubraca (rucaparib)

+

bosentan

2 interactions

Avoid/Use Alternative

rucaparib + bosentan

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise caution advised: combo may incr. bosentan levels, risk of adverse effects (hepatic metab. inhibited)

• cabozantinib
Rubraca (rucaparib)

+

cabozantinib

2 interactions

Avoid/Use Alternative

rucaparib + cabozantinib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chloramphenicol
Rubraca (rucaparib)

+

chloramphenicol

3 interactions

Avoid/Use Alternative

rucaparib + chloramphenicol

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• chloroquine
Rubraca (rucaparib)

+

chloroquine

1 interaction

Avoid/Use Alternative

rucaparib + chloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• citalopram
Rubraca (rucaparib)

+

citalopram

3 interactions

Avoid/Use Alternative

rucaparib + citalopram

use alternative or monitor ECG; adjust max citalopram dose to 20 mg/day: combo may incr. citalopram levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• cladribine oral
Rubraca (rucaparib)

+

cladribine oral

1 interaction

Avoid/Use Alternative

rucaparib + cladribine oral

use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited, additive effects)

• clarithromycin
Rubraca (rucaparib)

+

clarithromycin

2 interactions

Avoid/Use Alternative

rucaparib + clarithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clofazimine
Rubraca (rucaparib)

+

clofazimine

2 interactions

Avoid/Use Alternative

rucaparib + clofazimine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• crizotinib
Rubraca (rucaparib)

+

crizotinib

3 interactions

Avoid/Use Alternative

rucaparib + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dabigatran
Rubraca (rucaparib)

+

dabigatran

1 interaction

Avoid/Use Alternative

rucaparib + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• deferiprone
Rubraca (rucaparib)

+

deferiprone

1 interaction

Avoid/Use Alternative

rucaparib + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• degarelix
Rubraca (rucaparib)

+

degarelix

2 interactions

Avoid/Use Alternative

rucaparib + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desipramine
Rubraca (rucaparib)

+

desipramine

3 interactions

Avoid/Use Alternative

rucaparib + desipramine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine
Rubraca (rucaparib)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

rucaparib + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Rubraca (rucaparib)

+

dexmedetomidine injection

3 interactions

Avoid/Use Alternative

rucaparib + dexmedetomidine injection

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexrazoxane
Rubraca (rucaparib)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

rucaparib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• dofetilide
Rubraca (rucaparib)

+

dofetilide

3 interactions

Avoid/Use Alternative

rucaparib + dofetilide

use alternative or monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• donepezil
Rubraca (rucaparib)

+

donepezil

1 interaction

Avoid/Use Alternative

rucaparib + donepezil

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dordaviprone
Rubraca (rucaparib)

+

dordaviprone

3 interactions

Avoid/Use Alternative

rucaparib + dordaviprone

use alternative or monitor ECG, electrolytes; separate admin.: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Rubraca (rucaparib)

+

droperidol

1 interaction

Avoid/Use Alternative

rucaparib + droperidol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Rubraca (rucaparib)

+

efavirenz

1 interaction

Avoid/Use Alternative

rucaparib + efavirenz

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• encorafenib
Rubraca (rucaparib)

+

encorafenib

2 interactions

Avoid/Use Alternative

rucaparib + encorafenib

use alternative or monitor ECG, electrolytes: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ensartinib
Rubraca (rucaparib)

+

ensartinib

1 interaction

Avoid/Use Alternative

rucaparib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• entrectinib
Rubraca (rucaparib)

+

entrectinib

1 interaction

Avoid/Use Alternative

rucaparib + entrectinib

avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• ephedra
Rubraca (rucaparib)

+

ephedra

2 interactions

Avoid/Use Alternative

rucaparib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Rubraca (rucaparib)

+

eribulin

3 interactions

Avoid/Use Alternative

rucaparib + eribulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Rubraca (rucaparib)

+

erythromycin

1 interaction

Avoid/Use Alternative

rucaparib + erythromycin

use alternative or monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• etrasimod
Rubraca (rucaparib)

+

etrasimod

1 interaction

Avoid/Use Alternative

rucaparib + etrasimod

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• fexinidazole
Rubraca (rucaparib)

+

fexinidazole

2 interactions

Avoid/Use Alternative

rucaparib + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after rucaparib D/C; use alternative or monitor CBC, ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression; may decr. fexinidazole active metabolite levels, efficacy (additive effects; hepatic metab. inhibited, decr. conversion to active metabolites)

• flecainide
Rubraca (rucaparib)

+

flecainide

1 interaction

Avoid/Use Alternative

rucaparib + flecainide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Rubraca (rucaparib)

+

fluorouracil

3 interactions

Avoid/Use Alternative

rucaparib + fluorouracil

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Rubraca (rucaparib)

+

fluoxetine

1 interaction

Avoid/Use Alternative

rucaparib + fluoxetine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosfomycin injection
Rubraca (rucaparib)

+

fosfomycin injection

3 interactions

Avoid/Use Alternative

rucaparib + fosfomycin injection

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• ganciclovir
Rubraca (rucaparib)

+

ganciclovir

1 interaction

Avoid/Use Alternative

rucaparib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gepotidacin
Rubraca (rucaparib)

+

gepotidacin

2 interactions

Avoid/Use Alternative

rucaparib + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Rubraca (rucaparib)

+

gilteritinib

2 interactions

Avoid/Use Alternative

rucaparib + gilteritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• givinostat
Rubraca (rucaparib)

+

givinostat

2 interactions

Avoid/Use Alternative

rucaparib + givinostat

use alternative or monitor CBC, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• glasdegib
Rubraca (rucaparib)

+

glasdegib

2 interactions

Avoid/Use Alternative

rucaparib + glasdegib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• grapefruit
Rubraca (rucaparib)

+

grapefruit

3 interactions

Avoid/Use Alternative

rucaparib + grapefruit

use alternative or monitor ECG w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• haloperidol
Rubraca (rucaparib)

+

haloperidol

1 interaction

Avoid/Use Alternative

rucaparib + haloperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Rubraca (rucaparib)

+

histrelin

2 interactions

Avoid/Use Alternative

rucaparib + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Rubraca (rucaparib)

+

hydrocodone

2 interactions

Avoid/Use Alternative

rucaparib + hydrocodone

use alternative or monitor resp. rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• hydroxyzine
Rubraca (rucaparib)

+

hydroxyzine

3 interactions

Avoid/Use Alternative

rucaparib + hydroxyzine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Rubraca (rucaparib)

+

ibutilide

1 interaction

Avoid/Use Alternative

rucaparib + ibutilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• iloperidone
Rubraca (rucaparib)

+

iloperidone

1 interaction

Avoid/Use Alternative

rucaparib + iloperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• inotuzumab ozogamicin
Rubraca (rucaparib)

+

inotuzumab ozogamicin

2 interactions

Avoid/Use Alternative

rucaparib + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ivabradine
Rubraca (rucaparib)

+

ivabradine

3 interactions

Avoid/Use Alternative

rucaparib + ivabradine

consider alternative or monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ivosidenib
Rubraca (rucaparib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

rucaparib + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lefamulin
Rubraca (rucaparib)

+

lefamulin

2 interactions

Avoid/Use Alternative

rucaparib + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• leuprolide
Rubraca (rucaparib)

+

leuprolide

2 interactions

Avoid/Use Alternative

rucaparib + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Rubraca (rucaparib)

+

levofloxacin

1 interaction

Avoid/Use Alternative

rucaparib + levofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lofexidine
Rubraca (rucaparib)

+

lofexidine

2 interactions

Avoid/Use Alternative

rucaparib + lofexidine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Rubraca (rucaparib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

rucaparib + lonafarnib

use alternative or monitor HR, ECG, electrolytes, CBC: combo may incr. lonafarnib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• loperamide
Rubraca (rucaparib)

+

loperamide

1 interaction

Avoid/Use Alternative

rucaparib + loperamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Rubraca (rucaparib)

+

lopinavir/ ritonavir

2 interactions

Avoid/Use Alternative

rucaparib + lopinavir/ ritonavir

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• meperidine
Rubraca (rucaparib)

+

meperidine

3 interactions

Avoid/Use Alternative

rucaparib + meperidine

use alternative or monitor resp. rate, ECG: combo may incr. meperidine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• methadone
Rubraca (rucaparib)

+

methadone

1 interaction

Avoid/Use Alternative

rucaparib + methadone

use alternative or monitor resp. rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mifepristone
Rubraca (rucaparib)

+

mifepristone

2 interactions

Avoid/Use Alternative

rucaparib + mifepristone

use alternative or monitor ECG if daily mifepristone use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mobocertinib
Rubraca (rucaparib)

+

mobocertinib

2 interactions

Avoid/Use Alternative

rucaparib + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• moxifloxacin
Rubraca (rucaparib)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

rucaparib + moxifloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• neratinib
Rubraca (rucaparib)

+

neratinib

3 interactions

Avoid/Use Alternative

rucaparib + neratinib

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• nilotinib
Rubraca (rucaparib)

+

nilotinib

1 interaction

Avoid/Use Alternative

rucaparib + nilotinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oliceridine
Rubraca (rucaparib)

+

oliceridine

3 interactions

Avoid/Use Alternative

rucaparib + oliceridine

use alternative or monitor resp. rate, ECG: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ondansetron
Rubraca (rucaparib)

+

ondansetron

1 interaction

Avoid/Use Alternative

rucaparib + ondansetron

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Rubraca (rucaparib)

+

osimertinib

1 interaction

Avoid/Use Alternative

rucaparib + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Rubraca (rucaparib)

+

oxaliplatin

2 interactions

Avoid/Use Alternative

rucaparib + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ozanimod
Rubraca (rucaparib)

+

ozanimod

3 interactions

Avoid/Use Alternative

rucaparib + ozanimod

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palifermin
Rubraca (rucaparib)

+

palifermin

3 interactions

Avoid/Use Alternative

rucaparib + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• paliperidone
Rubraca (rucaparib)

+

paliperidone

1 interaction

Avoid/Use Alternative

rucaparib + paliperidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Rubraca (rucaparib)

+

palonosetron

1 interaction

Avoid/Use Alternative

rucaparib + palonosetron

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Rubraca (rucaparib)

+

pasireotide

1 interaction

Avoid/Use Alternative

rucaparib + pasireotide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Rubraca (rucaparib)

+

pazopanib

1 interaction

Avoid/Use Alternative

rucaparib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited, additive effects)

• penicillamine
Rubraca (rucaparib)

+

penicillamine

2 interactions

Avoid/Use Alternative

rucaparib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• phenobarbital
Rubraca (rucaparib)

+

phenobarbital

2 interactions

Avoid/Use Alternative

rucaparib + phenobarbital

avoid combo if neonatal seizure use; otherwise, monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pirfenidone
Rubraca (rucaparib)

+

pirfenidone

1 interaction

Avoid/Use Alternative

rucaparib + pirfenidone

avoid combo if also combined w/ mod-strong CYP2C9, CYP2C19, CYP2D6, or CYP2E1 inhibitor; otherwise, consider alternative or decr. pirfenidone dose to 534 mg tid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

• pitolisant
Rubraca (rucaparib)

+

pitolisant

2 interactions

Avoid/Use Alternative

rucaparib + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Rubraca (rucaparib)

+

ponesimod

1 interaction

Avoid/Use Alternative

rucaparib + ponesimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• porfimer
Rubraca (rucaparib)

+

porfimer

2 interactions

Avoid/Use Alternative

rucaparib + porfimer

avoid combo: combo may incr. risk of photosensitivity reaction (additive effects)

• primaquine
Rubraca (rucaparib)

+

primaquine

1 interaction

Avoid/Use Alternative

rucaparib + primaquine

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• procainamide
Rubraca (rucaparib)

+

procainamide

3 interactions

Avoid/Use Alternative

rucaparib + procainamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Rubraca (rucaparib)

+

propafenone

1 interaction

Avoid/Use Alternative

rucaparib + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, use alternative or monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• quetiapine
Rubraca (rucaparib)

+

quetiapine

2 interactions

Avoid/Use Alternative

rucaparib + quetiapine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (antiarrhythmic)
Rubraca (rucaparib)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

rucaparib + quinidine (antiarrhythmic)

use alternative or monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• quinine
Rubraca (rucaparib)

+

quinine

1 interaction

Avoid/Use Alternative

rucaparib + quinine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Rubraca (rucaparib)

+

quizartinib

2 interactions

Avoid/Use Alternative

rucaparib + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• radium Ra 223 dichloride
Rubraca (rucaparib)

+

radium Ra 223 dichloride

2 interactions

Avoid/Use Alternative

rucaparib + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• relugolix
Rubraca (rucaparib)

+

relugolix

1 interaction

Avoid/Use Alternative

rucaparib + relugolix

PROSTATE CANCER: may hold relugolix if rucaparib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before rucaparib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before rucaparib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• repotrectinib
Rubraca (rucaparib)

+

repotrectinib

2 interactions

Avoid/Use Alternative

rucaparib + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• revumenib
Rubraca (rucaparib)

+

revumenib

2 interactions

Avoid/Use Alternative

rucaparib + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Rubraca (rucaparib)

+

ribociclib

1 interaction

Avoid/Use Alternative

rucaparib + ribociclib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• rilpivirine
Rubraca (rucaparib)

+

rilpivirine

2 interactions

Avoid/Use Alternative

rucaparib + rilpivirine

consider alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• romidepsin
Rubraca (rucaparib)

+

romidepsin

2 interactions

Avoid/Use Alternative

rucaparib + romidepsin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Rubraca (rucaparib)

+

selpercatinib

1 interaction

Avoid/Use Alternative

rucaparib + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• sevoflurane
Rubraca (rucaparib)

+

sevoflurane

1 interaction

Avoid/Use Alternative

rucaparib + sevoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• simvastatin
Rubraca (rucaparib)

+

simvastatin

3 interactions

Avoid/Use Alternative

rucaparib + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, BCRP-mediated transport inhibited)

• siponimod
Rubraca (rucaparib)

+

siponimod

1 interaction

Avoid/Use Alternative

rucaparib + siponimod

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• sirolimus albumin-bound
Rubraca (rucaparib)

+

sirolimus albumin-bound

2 interactions

Avoid/Use Alternative

rucaparib + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• sorafenib
Rubraca (rucaparib)

+

sorafenib

1 interaction

Avoid/Use Alternative

rucaparib + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Rubraca (rucaparib)

+

sotalol

3 interactions

Avoid/Use Alternative

rucaparib + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• taletrectinib
Rubraca (rucaparib)

+

taletrectinib

1 interaction

Avoid/Use Alternative

rucaparib + taletrectinib

use alternative or monitor ECG, electrolytes: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• telavancin
Rubraca (rucaparib)

+

telavancin

2 interactions

Avoid/Use Alternative

rucaparib + telavancin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tizanidine
Rubraca (rucaparib)

+

tizanidine

2 interactions

Avoid/Use Alternative

rucaparib + tizanidine

use alternative or monitor BP, HR: combo may incr. tizanidine levels, risk of hypotension (including orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• toremifene
Rubraca (rucaparib)

+

toremifene

1 interaction

Avoid/Use Alternative

rucaparib + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Rubraca (rucaparib)

+

tramadol

3 interactions

Avoid/Use Alternative

rucaparib + tramadol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trazodone
Rubraca (rucaparib)

+

trazodone

1 interaction

Avoid/Use Alternative

rucaparib + trazodone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triclabendazole
Rubraca (rucaparib)

+

triclabendazole

2 interactions

Avoid/Use Alternative

rucaparib + triclabendazole

use alternative or monitor ECG: combo may incr. triclabendazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• triptorelin
Rubraca (rucaparib)

+

triptorelin

1 interaction

Avoid/Use Alternative

rucaparib + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• valganciclovir
Rubraca (rucaparib)

+

valganciclovir

3 interactions

Avoid/Use Alternative

rucaparib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Rubraca (rucaparib)

+

vandetanib

1 interaction

Avoid/Use Alternative

rucaparib + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Rubraca (rucaparib)

+

vemurafenib

2 interactions

Avoid/Use Alternative

rucaparib + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vorasidenib
Rubraca (rucaparib)

+

vorasidenib

2 interactions

Avoid/Use Alternative

rucaparib + vorasidenib

use alternative: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metab. inhibited)

Monitor/Modify Tx

• abemaciclib
Rubraca (rucaparib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

rucaparib + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Rubraca (rucaparib)

+

acalabrutinib

2 interactions

Monitor/Modify Tx

rucaparib + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• afatinib
Rubraca (rucaparib)

+

afatinib

1 interaction

Monitor/Modify Tx

rucaparib + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• aficamten
Rubraca (rucaparib)

+

aficamten

1 interaction

Monitor/Modify Tx

rucaparib + aficamten

monitor cardiac fxn, incl. LVEF: combo may incr. aficamten levels, risk of cardiotoxicity, other adverse effects (hepatic metab. inhibited)

• albendazole
Rubraca (rucaparib)

+

albendazole

3 interactions

Monitor/Modify Tx

rucaparib + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• albuterol
Rubraca (rucaparib)

+

albuterol

1 interaction

Monitor/Modify Tx

rucaparib + albuterol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Rubraca (rucaparib)

+

albuterol inhaled

2 interactions

Monitor/Modify Tx

rucaparib + albuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alemtuzumab
Rubraca (rucaparib)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

rucaparib + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• alfentanil
Rubraca (rucaparib)

+

alfentanil

1 interaction

Monitor/Modify Tx

rucaparib + alfentanil

monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• alfuzosin
Rubraca (rucaparib)

+

alfuzosin

3 interactions

Monitor/Modify Tx

rucaparib + alfuzosin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• allopurinol
Rubraca (rucaparib)

+

allopurinol

1 interaction

Monitor/Modify Tx

rucaparib + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• aminophylline
Rubraca (rucaparib)

+

aminophylline

2 interactions

Monitor/Modify Tx

rucaparib + aminophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of adverse effects (hepatic metab. inhibited; aminophylline converted to theophylline)

• amisulpride
Rubraca (rucaparib)

+

amisulpride

1 interaction

Monitor/Modify Tx

rucaparib + amisulpride

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Rubraca (rucaparib)

+

amitriptyline

2 interactions

Monitor/Modify Tx

rucaparib + amitriptyline

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anti-thymocyte globulin
Rubraca (rucaparib)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

rucaparib + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• arformoterol inhaled
Rubraca (rucaparib)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

rucaparib + arformoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asciminib
Rubraca (rucaparib)

+

asciminib

3 interactions

Monitor/Modify Tx

rucaparib + asciminib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atidarsagene autotemcel
Rubraca (rucaparib)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

rucaparib + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• atorvastatin
Rubraca (rucaparib)

+

atorvastatin

2 interactions

Monitor/Modify Tx

rucaparib + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• auranofin
Rubraca (rucaparib)

+

auranofin

1 interaction

Monitor/Modify Tx

rucaparib + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avanafil
Rubraca (rucaparib)

+

avanafil

2 interactions

Monitor/Modify Tx

rucaparib + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avapritinib
Rubraca (rucaparib)

+

avapritinib

1 interaction

Monitor/Modify Tx

rucaparib + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited)

• azathioprine
Rubraca (rucaparib)

+

azathioprine

1 interaction

Monitor/Modify Tx

rucaparib + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• balsalazide
Rubraca (rucaparib)

+

balsalazide

1 interaction

Monitor/Modify Tx

rucaparib + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Rubraca (rucaparib)

+

baricitinib

3 interactions

Monitor/Modify Tx

rucaparib + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benznidazole
Rubraca (rucaparib)

+

benznidazole

1 interaction

Monitor/Modify Tx

rucaparib + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• berotralstat
Rubraca (rucaparib)

+

berotralstat

1 interaction

Monitor/Modify Tx

rucaparib + berotralstat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• betibeglogene autotemcel
Rubraca (rucaparib)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

rucaparib + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• brigatinib
Rubraca (rucaparib)

+

brigatinib

2 interactions

Monitor/Modify Tx

rucaparib + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metab. inhibited)

• buprenorphine
Rubraca (rucaparib)

+

buprenorphine

2 interactions

Monitor/Modify Tx

rucaparib + buprenorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• caffeine citrate
Rubraca (rucaparib)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

rucaparib + caffeine citrate

monitor caffeine levels: combo may incr. caffeine levels, risk of adverse effects (hepatic metab. inhibited)

• capivasertib
Rubraca (rucaparib)

+

capivasertib

1 interaction

Monitor/Modify Tx

rucaparib + capivasertib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• carbamazepine
Rubraca (rucaparib)

+

carbamazepine

1 interaction

Monitor/Modify Tx

rucaparib + carbamazepine

monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects (hepatic metab. inhibited)

• celecoxib
Rubraca (rucaparib)

+

celecoxib

3 interactions

Monitor/Modify Tx

rucaparib + celecoxib

monitor bleeding s/sx: combo may incr. celecoxib levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited)

• chlorpromazine
Rubraca (rucaparib)

+

chlorpromazine

2 interactions

Monitor/Modify Tx

rucaparib + chlorpromazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cidofovir
Rubraca (rucaparib)

+

cidofovir

2 interactions

Monitor/Modify Tx

rucaparib + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ciprofloxacin
Rubraca (rucaparib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

rucaparib + ciprofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clobazam
Rubraca (rucaparib)

+

clobazam

1 interaction

Monitor/Modify Tx

rucaparib + clobazam

monitor resp. rate: combo may incr. clobazam and active metabolite levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clomipramine
Rubraca (rucaparib)

+

clomipramine

3 interactions

Monitor/Modify Tx

rucaparib + clomipramine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clozapine
Rubraca (rucaparib)

+

clozapine

2 interactions

Monitor/Modify Tx

rucaparib + clozapine

monitor CBC, ECG, BP, HR, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• copper histidinate
Rubraca (rucaparib)

+

copper histidinate

1 interaction

Monitor/Modify Tx

rucaparib + copper histidinate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cyclophosphamide
Rubraca (rucaparib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

rucaparib + cyclophosphamide

monitor CBC: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of myelosuppression (hepatic metab. possibly inhibited, decr. conversion to active metabolite; additive effects)

• cyclosporine
Rubraca (rucaparib)

+

cyclosporine

3 interactions

Monitor/Modify Tx

rucaparib + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited)

• dapsone
Rubraca (rucaparib)

+

dapsone

2 interactions

Monitor/Modify Tx

rucaparib + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dasatinib
Rubraca (rucaparib)

+

dasatinib

1 interaction

Monitor/Modify Tx

rucaparib + dasatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• deferasirox
Rubraca (rucaparib)

+

deferasirox

1 interaction

Monitor/Modify Tx

rucaparib + deferasirox

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deuruxolitinib
Rubraca (rucaparib)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

rucaparib + deuruxolitinib

monitor CBC, thrombosis s/sx: combo may incr. deuruxolitinib levels, risk of serious infection, thromboembolism, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• deutetrabenazine
Rubraca (rucaparib)

+

deutetrabenazine

2 interactions

Monitor/Modify Tx

rucaparib + deutetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• diazepam
Rubraca (rucaparib)

+

diazepam

1 interaction

Monitor/Modify Tx

rucaparib + diazepam

monitor resp. rate: combo may incr. diazepam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• diclofenac
Rubraca (rucaparib)

+

diclofenac

1 interaction

Monitor/Modify Tx

rucaparib + diclofenac

monitor bleeding s/sx; use lowest effective diclofenac dose, shortest duration of concomitant tx: combo may incr. diclofenac levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited)

• digoxin
Rubraca (rucaparib)

+

digoxin

2 interactions

Monitor/Modify Tx

rucaparib + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• docetaxel
Rubraca (rucaparib)

+

docetaxel

1 interaction

Monitor/Modify Tx

rucaparib + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• edoxaban
Rubraca (rucaparib)

+

edoxaban

1 interaction

Monitor/Modify Tx

rucaparib + edoxaban

monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• efbemalenograstim alfa
Rubraca (rucaparib)

+

efbemalenograstim alfa

2 interactions

Monitor/Modify Tx

rucaparib + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Rubraca (rucaparib)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

rucaparib + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elivaldogene autotemcel
Rubraca (rucaparib)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

rucaparib + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• enfortumab vedotin
Rubraca (rucaparib)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

rucaparib + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

• escitalopram
Rubraca (rucaparib)

+

escitalopram

2 interactions

Monitor/Modify Tx

rucaparib + escitalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• etuvetidigene autotemcel
Rubraca (rucaparib)

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

rucaparib + etuvetidigene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• everolimus
Rubraca (rucaparib)

+

everolimus

2 interactions

Monitor/Modify Tx

rucaparib + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• exagamglogene autotemcel
Rubraca (rucaparib)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

rucaparib + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fedratinib
Rubraca (rucaparib)

+

fedratinib

2 interactions

Monitor/Modify Tx

rucaparib + fedratinib

monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• felodipine
Rubraca (rucaparib)

+

felodipine

1 interaction

Monitor/Modify Tx

rucaparib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• fentanyl
Rubraca (rucaparib)

+

fentanyl

2 interactions

Monitor/Modify Tx

rucaparib + fentanyl

monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• filgrastim (G-CSF)
Rubraca (rucaparib)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

rucaparib + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• finerenone
Rubraca (rucaparib)

+

finerenone

1 interaction

Monitor/Modify Tx

rucaparib + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• fingolimod
Rubraca (rucaparib)

+

fingolimod

3 interactions

Monitor/Modify Tx

rucaparib + fingolimod

monitor ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flibanserin
Rubraca (rucaparib)

+

flibanserin

1 interaction

Monitor/Modify Tx

rucaparib + flibanserin

monitor BP: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metab. inhibited)

• fluconazole
Rubraca (rucaparib)

+

fluconazole

2 interactions

Monitor/Modify Tx

rucaparib + fluconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flucytosine
Rubraca (rucaparib)

+

flucytosine

1 interaction

Monitor/Modify Tx

rucaparib + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluphenazine
Rubraca (rucaparib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

rucaparib + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluvastatin
Rubraca (rucaparib)

+

fluvastatin

3 interactions

Monitor/Modify Tx

rucaparib + fluvastatin

monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, BCRP-mediated transport inhibited)

• formoterol inhaled
Rubraca (rucaparib)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

rucaparib + formoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosphenytoin
Rubraca (rucaparib)

+

fosphenytoin

2 interactions

Monitor/Modify Tx

rucaparib + fosphenytoin

monitor phenytoin levels: combo may incr. fosphenytoin levels, risk of adverse effects (hepatic metab. inhibited)

• fostamatinib
Rubraca (rucaparib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

rucaparib + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fostemsavir
Rubraca (rucaparib)

+

fostemsavir

1 interaction

Monitor/Modify Tx

rucaparib + fostemsavir

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gemtuzumab ozogamicin
Rubraca (rucaparib)

+

gemtuzumab ozogamicin

2 interactions

Monitor/Modify Tx

rucaparib + gemtuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepirone
Rubraca (rucaparib)

+

gepirone

1 interaction

Monitor/Modify Tx

rucaparib + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• glimepiride
Rubraca (rucaparib)

+

glimepiride

1 interaction

Monitor/Modify Tx

rucaparib + glimepiride

monitor glucose: combo may incr. glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• granisetron
Rubraca (rucaparib)

+

granisetron

3 interactions

Monitor/Modify Tx

rucaparib + granisetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyurea
Rubraca (rucaparib)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

rucaparib + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ibrutinib
Rubraca (rucaparib)

+

ibrutinib

2 interactions

Monitor/Modify Tx

rucaparib + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• imatinib
Rubraca (rucaparib)

+

imatinib

1 interaction

Monitor/Modify Tx

rucaparib + imatinib

monitor CBC: combo may incr. imatinib levels, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited)

• interferon beta 1a
Rubraca (rucaparib)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

rucaparib + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Rubraca (rucaparib)

+

interferon beta 1b

3 interactions

Monitor/Modify Tx

rucaparib + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Rubraca (rucaparib)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

rucaparib + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• irinotecan
Rubraca (rucaparib)

+

irinotecan

2 interactions

Monitor/Modify Tx

rucaparib + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport inhibited)

• ixabepilone
Rubraca (rucaparib)

+

ixabepilone

1 interaction

Monitor/Modify Tx

rucaparib + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• lapatinib
Rubraca (rucaparib)

+

lapatinib

1 interaction

Monitor/Modify Tx

rucaparib + lapatinib

monitor ECG: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited, additive effects)

• leflunomide
Rubraca (rucaparib)

+

leflunomide

3 interactions

Monitor/Modify Tx

rucaparib + leflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lemborexant
Rubraca (rucaparib)

+

lemborexant

1 interaction

Monitor/Modify Tx

rucaparib + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lenvatinib
Rubraca (rucaparib)

+

lenvatinib

1 interaction

Monitor/Modify Tx

rucaparib + lenvatinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levalbuterol inhaled
Rubraca (rucaparib)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

rucaparib + levalbuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lidocaine
Rubraca (rucaparib)

+

lidocaine

2 interactions

Monitor/Modify Tx

rucaparib + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metab. inhibited)

• linezolid
Rubraca (rucaparib)

+

linezolid

1 interaction

Monitor/Modify Tx

rucaparib + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lomitapide
Rubraca (rucaparib)

+

lomitapide

1 interaction

Monitor/Modify Tx

rucaparib + lomitapide

max lomitapide dose 30 mg/day: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• lovastatin
Rubraca (rucaparib)

+

lovastatin

1 interaction

Monitor/Modify Tx

rucaparib + lovastatin

monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lovotibeglogene autotemcel
Rubraca (rucaparib)

+

lovotibeglogene autotemcel

3 interactions

Monitor/Modify Tx

rucaparib + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumateperone
Rubraca (rucaparib)

+

lumateperone

1 interaction

Monitor/Modify Tx

rucaparib + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lurasidone
Rubraca (rucaparib)

+

lurasidone

3 interactions

Monitor/Modify Tx

rucaparib + lurasidone

monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lurbinectedin
Rubraca (rucaparib)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

rucaparib + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• lymphocyte immune globulin, anti-thymocyte globulin
Rubraca (rucaparib)

+

lymphocyte immune globulin, anti-thymocyte globulin

2 interactions

Monitor/Modify Tx

rucaparib + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mavacamten
Rubraca (rucaparib)

+

mavacamten

1 interaction

Monitor/Modify Tx

rucaparib + mavacamten

monitor cardiac fxn, incl. LVEF; if patient stable on rucaparib tx, initiate mavacamten at 5 mg qd; if adding short-term (<1wk) rucaparib tx to existing mavacamten tx, hold mavacamten until rucaparib D/C; if adding longer-term (>1wk) rucaparib tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start rucaparib tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metab. inhibited)

• mavorixafor
Rubraca (rucaparib)

+

mavorixafor

2 interactions

Monitor/Modify Tx

rucaparib + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• mefloquine
Rubraca (rucaparib)

+

mefloquine

1 interaction

Monitor/Modify Tx

rucaparib + mefloquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mercaptopurine
Rubraca (rucaparib)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

rucaparib + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Rubraca (rucaparib)

+

mesalamine

3 interactions

Monitor/Modify Tx

rucaparib + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Rubraca (rucaparib)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

rucaparib + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methotrexate
Rubraca (rucaparib)

+

methotrexate

3 interactions

Monitor/Modify Tx

rucaparib + methotrexate

monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited, additive effects)

• metronidazole
Rubraca (rucaparib)

+

metronidazole

1 interaction

Monitor/Modify Tx

rucaparib + metronidazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midazolam
Rubraca (rucaparib)

+

midazolam

2 interactions

Monitor/Modify Tx

rucaparib + midazolam

monitor resp. rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• midostaurin
Rubraca (rucaparib)

+

midostaurin

1 interaction

Monitor/Modify Tx

rucaparib + midostaurin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mirtazapine
Rubraca (rucaparib)

+

mirtazapine

1 interaction

Monitor/Modify Tx

rucaparib + mirtazapine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• morphine
Rubraca (rucaparib)

+

morphine

1 interaction

Monitor/Modify Tx

rucaparib + morphine

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• mycophenolate mofetil
Rubraca (rucaparib)

+

mycophenolate mofetil

2 interactions

Monitor/Modify Tx

rucaparib + mycophenolate mofetil

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mycophenolic acid
Rubraca (rucaparib)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

rucaparib + mycophenolic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• nifedipine
Rubraca (rucaparib)

+

nifedipine

2 interactions

Monitor/Modify Tx

rucaparib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nimodipine
Rubraca (rucaparib)

+

nimodipine

1 interaction

Monitor/Modify Tx

rucaparib + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Rubraca (rucaparib)

+

nisoldipine

2 interactions

Monitor/Modify Tx

rucaparib + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• ofloxacin
Rubraca (rucaparib)

+

ofloxacin

1 interaction

Monitor/Modify Tx

rucaparib + ofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Rubraca (rucaparib)

+

olodaterol inhaled

2 interactions

Monitor/Modify Tx

rucaparib + olodaterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olsalazine
Rubraca (rucaparib)

+

olsalazine

1 interaction

Monitor/Modify Tx

rucaparib + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• osilodrostat
Rubraca (rucaparib)

+

osilodrostat

2 interactions

Monitor/Modify Tx

rucaparib + osilodrostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pegfilgrastim (G-CSF)
Rubraca (rucaparib)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

rucaparib + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon beta 1a
Rubraca (rucaparib)

+

peginterferon beta 1a

2 interactions

Monitor/Modify Tx

rucaparib + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pemigatinib
Rubraca (rucaparib)

+

pemigatinib

1 interaction

Monitor/Modify Tx

rucaparib + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• phenytoin
Rubraca (rucaparib)

+

phenytoin

1 interaction

Monitor/Modify Tx

rucaparib + phenytoin

monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity (hepatic metab. inhibited)

• pitavastatin
Rubraca (rucaparib)

+

pitavastatin

3 interactions

Monitor/Modify Tx

rucaparib + pitavastatin

monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)

• pomalidomide
Rubraca (rucaparib)

+

pomalidomide

1 interaction

Monitor/Modify Tx

rucaparib + pomalidomide

monitor CBC: combo may incr. pomalidomide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• posaconazole
Rubraca (rucaparib)

+

posaconazole

2 interactions

Monitor/Modify Tx

rucaparib + posaconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pravastatin
Rubraca (rucaparib)

+

pravastatin

1 interaction

Monitor/Modify Tx

rucaparib + pravastatin

monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)

• proguanil
Rubraca (rucaparib)

+

proguanil

1 interaction

Monitor/Modify Tx

rucaparib + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. proguanil levels, risk of myelosuppression, other adverse effects; may decr. proguanil active metabolite levels, efficacy (hepatic metab. inhibited, decr. conversion to active metabolite; additive effects)

• promethazine
Rubraca (rucaparib)

+

promethazine

2 interactions

Monitor/Modify Tx

rucaparib + promethazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propranolol
Rubraca (rucaparib)

+

propranolol

1 interaction

Monitor/Modify Tx

rucaparib + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. inhibited)

• pyrimethamine
Rubraca (rucaparib)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

rucaparib + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ranolazine
Rubraca (rucaparib)

+

ranolazine

2 interactions

Monitor/Modify Tx

rucaparib + ranolazine

monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• rasagiline
Rubraca (rucaparib)

+

rasagiline

1 interaction

Monitor/Modify Tx

rucaparib + rasagiline

adjust max rasagiline dose to 0.5 mg/day: combo may incr. rasagiline levels, risk of adverse effects (hepatic metab. inhibited)

• red yeast rice
Rubraca (rucaparib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

rucaparib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• rifabutin
Rubraca (rucaparib)

+

rifabutin

1 interaction

Monitor/Modify Tx

rucaparib + rifabutin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• riociguat
Rubraca (rucaparib)

+

riociguat

2 interactions

Monitor/Modify Tx

rucaparib + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (BCRP-mediated transport inhibited)

• rituximab
Rubraca (rucaparib)

+

rituximab

1 interaction

Monitor/Modify Tx

rucaparib + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ropinirole
Rubraca (rucaparib)

+

ropinirole

1 interaction

Monitor/Modify Tx

rucaparib + ropinirole

consider decr. ropinirole dose: combo may incr. ropinirole levels, risk of adverse effects (hepatic metab. inhibited)

• rosuvastatin
Rubraca (rucaparib)

+

rosuvastatin

1 interaction

Monitor/Modify Tx

rucaparib + rosuvastatin

monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited)

• ruxolitinib topical
Rubraca (rucaparib)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

rucaparib + ruxolitinib topical

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sacituzumab govitecan
Rubraca (rucaparib)

+

sacituzumab govitecan

3 interactions

Monitor/Modify Tx

rucaparib + sacituzumab govitecan

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• salmeterol inhaled
Rubraca (rucaparib)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

rucaparib + salmeterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sargramostim (GM-CSF)
Rubraca (rucaparib)

+

sargramostim (GM-CSF)

2 interactions

Monitor/Modify Tx

rucaparib + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Rubraca (rucaparib)

+

sarilumab

1 interaction

Monitor/Modify Tx

rucaparib + sarilumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• satralizumab
Rubraca (rucaparib)

+

satralizumab

1 interaction

Monitor/Modify Tx

rucaparib + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sebetralstat
Rubraca (rucaparib)

+

sebetralstat

3 interactions

Monitor/Modify Tx

rucaparib + sebetralstat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sirolimus
Rubraca (rucaparib)

+

sirolimus

1 interaction

Monitor/Modify Tx

rucaparib + sirolimus

monitor sirolimus levels, CBC: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• stiripentol
Rubraca (rucaparib)

+

stiripentol

3 interactions

Monitor/Modify Tx

rucaparib + stiripentol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succimer
Rubraca (rucaparib)

+

succimer

1 interaction

Monitor/Modify Tx

rucaparib + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sufentanil
Rubraca (rucaparib)

+

sufentanil

2 interactions

Monitor/Modify Tx

rucaparib + sufentanil

monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• sulfasalazine
Rubraca (rucaparib)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

rucaparib + sulfasalazine

monitor CBC: combo may incr. sulfasalazine levels, risk of myelosuppression, other adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited, additive effects)

• sunitinib
Rubraca (rucaparib)

+

sunitinib

2 interactions

Monitor/Modify Tx

rucaparib + sunitinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tacrolimus
Rubraca (rucaparib)

+

tacrolimus

1 interaction

Monitor/Modify Tx

rucaparib + tacrolimus

monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• tadalafil
Rubraca (rucaparib)

+

tadalafil

2 interactions

Monitor/Modify Tx

rucaparib + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• tazemetostat
Rubraca (rucaparib)

+

tazemetostat

1 interaction

Monitor/Modify Tx

rucaparib + tazemetostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• temsirolimus
Rubraca (rucaparib)

+

temsirolimus

3 interactions

Monitor/Modify Tx

rucaparib + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• tenofovir alafenamide
Rubraca (rucaparib)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

rucaparib + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

• tenofovir disoproxil
Rubraca (rucaparib)

+

tenofovir disoproxil

2 interactions

Monitor/Modify Tx

rucaparib + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

• teplizumab
Rubraca (rucaparib)

+

teplizumab

1 interaction

Monitor/Modify Tx

rucaparib + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• terbutaline
Rubraca (rucaparib)

+

terbutaline

1 interaction

Monitor/Modify Tx

rucaparib + terbutaline

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• teriflunomide
Rubraca (rucaparib)

+

teriflunomide

1 interaction

Monitor/Modify Tx

rucaparib + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• thalidomide
Rubraca (rucaparib)

+

thalidomide

1 interaction

Monitor/Modify Tx

rucaparib + thalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• theophylline
Rubraca (rucaparib)

+

theophylline

3 interactions

Monitor/Modify Tx

rucaparib + theophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of adverse effects (hepatic metab. inhibited)

• tocilizumab
Rubraca (rucaparib)

+

tocilizumab

1 interaction

Monitor/Modify Tx

rucaparib + tocilizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tofacitinib
Rubraca (rucaparib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

rucaparib + tofacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tolterodine
Rubraca (rucaparib)

+

tolterodine

3 interactions

Monitor/Modify Tx

rucaparib + tolterodine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tolvaptan
Rubraca (rucaparib)

+

tolvaptan

1 interaction

Monitor/Modify Tx

rucaparib + tolvaptan

consider decr. tolvaptan dose: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metab. inhibited)

• torsemide
Rubraca (rucaparib)

+

torsemide

2 interactions

Monitor/Modify Tx

rucaparib + torsemide

monitor renal fxn, BP: combo may incr. torsemide levels, risk of nephrotoxicity, hypotension, other adverse effects (hepatic metab. inhibited)

• trimethoprim
Rubraca (rucaparib)

+

trimethoprim

1 interaction

Monitor/Modify Tx

rucaparib + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ubrogepant
Rubraca (rucaparib)

+

ubrogepant

2 interactions

Monitor/Modify Tx

rucaparib + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• upadacitinib
Rubraca (rucaparib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

rucaparib + upadacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• valbenazine
Rubraca (rucaparib)

+

valbenazine

2 interactions

Monitor/Modify Tx

rucaparib + valbenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valproic acid
Rubraca (rucaparib)

+

valproic acid

1 interaction

Monitor/Modify Tx

rucaparib + valproic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vancomycin
Rubraca (rucaparib)

+

vancomycin

1 interaction

Monitor/Modify Tx

rucaparib + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vardenafil
Rubraca (rucaparib)

+

vardenafil

3 interactions

Monitor/Modify Tx

rucaparib + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited, additive effects)

• venlafaxine
Rubraca (rucaparib)

+

venlafaxine

1 interaction

Monitor/Modify Tx

rucaparib + venlafaxine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vilanterol inhaled
Rubraca (rucaparib)

+

vilanterol inhaled

2 interactions

Monitor/Modify Tx

rucaparib + vilanterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vinblastine
Rubraca (rucaparib)

+

vinblastine

1 interaction

Monitor/Modify Tx

rucaparib + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vincristine
Rubraca (rucaparib)

+

vincristine

1 interaction

Monitor/Modify Tx

rucaparib + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Rubraca (rucaparib)

+

vinorelbine

2 interactions

Monitor/Modify Tx

rucaparib + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• voclosporin
Rubraca (rucaparib)

+

voclosporin

1 interaction

Monitor/Modify Tx

rucaparib + voclosporin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voriconazole
Rubraca (rucaparib)

+

voriconazole

1 interaction

Monitor/Modify Tx

rucaparib + voriconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• warfarin
Rubraca (rucaparib)

+

warfarin

2 interactions

Monitor/Modify Tx

rucaparib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metab. inhibited)

• zanubrutinib
Rubraca (rucaparib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

rucaparib + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• zidovudine
Rubraca (rucaparib)

+

zidovudine

2 interactions

Monitor/Modify Tx

rucaparib + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)